Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$28.70 USD
+1.48 (5.44%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $28.64 -0.06 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SYRE 28.70 +1.48(5.44%)
Will SYRE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SYRE
Spyre Therapeutics appoints Sheldon Sloan as CMO
Spyre Therapeutics appoints Sloan as Chief Medical Officer
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
SYRE Makes Notable Cross Below Critical Moving Average
Spyre Therapeutics files to sell 46.33M shares of common stock for holders